Find the Perfect Plan for Your Investment Journey
Last Price
52 Week Range
$525.99 - $1.21K
Next Earnings Date
Jul 30 2025 (Estimate)
Next Earnings Date
Jul 30 2025 (Est.)
Last Price
Market Cap | $60.89B |
EV | $45.97B |
Shares Outstanding | 107.49M |
Beta | 0.44 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $844.67 |
P/E 2025E | 15.21x |
P/Revenue 2025E | 4.29x |
Revenue | -4.00% |
EPS | -15.10% |
Operating Cash Flow | -14.50% |
Free Cash Flow | -17.50% |
Revenue | 5.10% |
EPS | 4.10% |
Operating Cash Flow | 5.80% |
Free Cash Flow | 17.60% |
Gross Margin 2025E | 86.90% |
Net Profit Margin 2025E | 26.54% |
ROE 2025E | 16.55% |
ROCE 2024 | 15.95% |
DPS 2025E | $2.83 |
Payout Ratio 2025E | 7.57% |
Div. Yield 2025E | 0.50% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Regeneron Pharmaceuticals, Inc.
REGN
Sector
Healthcare
Industry
Biotechnology
CEO
Schleifer, Leonard
Employees
15,106
Website
www.regeneron.comIPO Date
1991-04-02
Headquarters
777 Old Saw Mill River Road, Tarrytown, New York, 10591-6707, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved